Arcus Stock Analysis

RCUS -  USA Stock  

USD 29.40  0.62  2.07%

The latest indifference towards the small price fluctuations of Arcus Biosciences created some momentum for retail investors as it was traded today as low as 29.24 and as high as 30.33 per share. The company directors and management did not add any value to Arcus Biosciences investors in July. However, most investors can still diversify their portfolios with Arcus Biosciences to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.44. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Arcus Biosciences partners.
Additionally, take a look at Your Equity Center.

Search Stock Analysis 

 
Refresh
The Arcus Biosciences stock analysis report makes it easy to digest most publicly released information about Arcus Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arcus Stock analysis module also helps to analyze the Arcus Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Arcus Stock Analysis Notes

About 38.0% of the company outstanding shares are owned by corporate insiders. The book value of Arcus Biosciences was at this time reported as 7.71. The company recorded a loss per share of 2.24. Arcus Biosciences had not issued any dividends in recent years. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 236 people. To find out more about Arcus Biosciences contact Terry Rosen at 510 694 6200 or learn more at http://www.arcusbio.com.

Arcus Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arcus Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcus Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arcus Biosciences has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 77.52 M. Net Loss for the year was (122.86 M) with loss before overhead, payroll, taxes, and interest of (81.83 M).
About 57.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: Infinity falls 9.22 percent in Light Trading on August 3 - Equities.com

Arcus Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcus Biosciences's market, we take the total number of its shares issued and multiply it by Arcus Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Arcus Profitablity

Arcus Biosciences' profitability indicators refer to fundamental financial ratios that showcase Arcus Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Arcus Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arcus Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arcus Biosciences' profitability requires more research than a typical breakdown of Arcus Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (158.49) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (160.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.6.

Management Efficiency

The entity has return on total asset (ROA) of (15.92) % which means that it has lost $15.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (36.89) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences management efficiency ratios could be used to measure how well arcus biosciences manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 5th of August, Arcus Biosciences shows the risk adjusted performance of (0.027636), and Mean Deviation of 2.41. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcus Biosciences, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Arcus Biosciences, which can be compared to its rivals. Please confirm Arcus Biosciences mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Arcus Biosciences is priced correctly, providing market reflects its regular price of 29.4 per share. Given that Arcus Biosciences has jensen alpha of (0.20), we suggest you to validate Arcus Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Arcus Biosciences Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arcus Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arcus Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Arcus Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Arcus Biosciences Predictive Daily Indicators

Arcus Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arcus Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Arcus Biosciences Forecast Models

Arcus Biosciences time-series forecasting models is one of many Arcus Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arcus Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Arcus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arcus Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arcus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Arcus Biosciences. By using and applying Arcus Stock analysis, traders can create a robust methodology for identifying Arcus entry and exit points for their positions.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 236 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Arcus Biosciences to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module
Additionally, take a look at Your Equity Center. Note that the Arcus Biosciences information on this page should be used as a complementary analysis to other Arcus Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Arcus Stock analysis

When running Arcus Biosciences price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Arcus Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.